United Therapeutics Corporation

HQ
Silver Spring, Maryland, USA
945 Total Employees
Year Founded: 1996
View Website

Similar Companies Hiring

Thrive Market Logo

Thrive Market

Consumer Web • eCommerce • Food • Healthtech • Natural Language Processing • Social Impact
Fully Remote, US
1000 Employees
TigerConnect Logo

TigerConnect

Cloud • Enterprise Web • Healthtech • Mobile • Software
2 Offices
329 Employees
Artera Logo

Artera

Healthtech • Other • Sales • Software • Analytics • Conversational AI
10 Offices
250 Employees

United Therapeutics Corporation Company Stability & Growth

Updated on February 06, 2026

This page was generated by Built In using publicly available information and AI-based analysis of common questions about the company. It has not been reviewed or approved by the company.

What's the stability & growth outlook for United Therapeutics Corporation?

Strengths in revenue momentum, category leadership in prostacyclin therapies, and a robust innovation pipeline are accompanied by concentration in treprostinil and intensifying competitive and pricing pressures. Together, these dynamics suggest a resilient growth profile that remains sensitive to competitive outcomes and the timing and success of late-stage clinical and regulatory milestones.
Positive Themes About United Therapeutics Corporation
  • Strong Revenue Growth: Revenue reached record levels in 2024 and continued to set quarterly records in 2025, led by the Tyvaso franchise. Management highlighted sustained momentum with multiple quarters of year-over-year increases.
  • Strong Market Position & Advantage: The company dominates prostacyclin therapies in PAH/PH-ILD and is a first mover in xenotransplantation and organ-access services. Physician adoption of Tyvaso DPI and leadership in EVLP/xeno programs reinforce category leadership in defined lanes.
  • Innovation-Driven Growth: Late-stage catalysts such as positive TETON-2 IPF data and the nearing ralinepag Phase 3 readout position the portfolio to expand beyond current indications. Active clinical xenotransplantation efforts and infrastructure build-out provide additional long-term growth avenues.
Considerations About United Therapeutics Corporation
  • Undiversified Revenue Streams: Growth is heavily tied to treprostinil products (Tyvaso, Orenitram, Remodulin), creating concentration risk despite diversification efforts. Pipeline and organ initiatives aim to broaden the base but still carry clinical, regulatory, and adoption risk.
  • Weak Market Position & Pricing Challenges: Direct competition from Liquidia’s FDA-approved Yutrepia and emerging once-daily inhaled treprostinil candidates, alongside Part D and gross-to-net dynamics, introduce share and pricing pressure for Tyvaso DPI. The arrival of sotatercept (Winrevair) reshapes treatment algorithms and budget allocation within PAH.
NEW
What does AI tell candidates about your employer brand?
Get your free AI reputation report today.
See AI Report
AI Report
AI Report
The insights on this page are generated by submitting structured prompts to some of the most popular large language models (“LLMs”) and summarizing recurring themes from the responses. Because the insights are generated using AI, they may contain errors. The insights do not necessarily reflect internal data, employee interviews, or verified company information. They may be influenced by incomplete, outdated, or inaccurate data, and may vary across LLM providers. These insights are intended for informational purposes only and should not be interpreted as a factual or definitive assessment of a company's reputation. Built In makes no representations or warranties regarding the accuracy, completeness, or reliability of this information, and disclaims any liability for any actions taken based on this information. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.
View All 32 Jobs at United Therapeutics Corporation
Is This Your Company? Claim Profile